Erlotinib Completed Phase 2 Trials for Renal Cell Adenocarcinoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00353301Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma